Omniab Stock Earnings Reports

OmniAb reported a strong Q1 2026 driven by partner progress, with total revenue of $14.4M (vs. $4.2M YoY) primarily from milestone payments. The company highlighted growth in partner-derived clinical programs (32 clinical/approved programs; 409 active programs total) and technology momentum — notably two OmnidAb-derived programs entering the clinic (one now in Phase II) and the recent launch of OmniUltra (a transgenic chicken that produces ultra-long CDRH3 antibodies) plus continued commercial interest in xPloration, their high-throughput single B-cell screening platform. OmniAb reiterated its business model focus on milestone and eventual royalty streams (average contracted royalty ~3.4%; >$3B in total contracted milestones across the portfolio) and noted growing partner interest including academia deals structured to share downstream economics. Financially, Q1 operating expenses were $22.3M (down vs. prior year after a $2.9M noncash write-off), net loss was $7.7M ($0.06/shr), cash at quarter end was $49.1M, and management raised full-year 2026 revenue guidance to $28–33M while maintaining cash operating expense guidance of $50–55M and projecting year-end cash of $33–38M. Key upcoming catalysts include multiple partner clinical readouts in 2026 (notably Teva’s TEV-408 vitiligo data in H1) and ASCO presentations that could increase visibility for OmniAb-derived assets.